Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0T1FC
|
|||
| Former ID |
DIB001524
|
|||
| Drug Name |
PF-4878691
|
|||
| Synonyms |
PF-04878691; PF-4171455
Click to Show/Hide
|
|||
| Indication | Melanoma [ICD-11: 2C30; ICD-9: 172] | Phase 2 | [1] | |
| Hepatitis C virus infection [ICD-11: 1E51.1; ICD-10: B18.2] | Phase 1 | [2] | ||
| Company |
Pfizer Inc
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C17H23N5O2S
|
|||
| Canonical SMILES |
CCC1=NC2=C(N1CCCCNS(=O)(=O)C)C3=CC=CC=C3N=C2N
|
|||
| InChI |
1S/C17H23N5O2S/c1-3-14-21-15-16(12-8-4-5-9-13(12)20-17(15)18)22(14)11-7-6-10-19-25(2,23)24/h4-5,8-9,19H,3,6-7,10-11H2,1-2H3,(H2,18,20)
|
|||
| InChIKey |
YZOQZEXYFLXNKA-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 532959-63-0
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Toll-like receptor 7 (TLR7) | Target Info | Agonist | [3] |
| KEGG Pathway | Toll-like receptor signaling pathway | |||
| Measles | ||||
| Influenza A | ||||
| NetPath Pathway | TCR Signaling Pathway | |||
| Panther Pathway | Toll receptor signaling pathway | |||
| Reactome | Trafficking and processing of endosomal TLR | |||
| TRAF6 mediated IRF7 activation in TLR7/8 or 9 signaling | ||||
| TRAF6 mediated induction of NFkB and MAP kinases upon TLR7/8 or 9 activation | ||||
| MyD88 dependent cascade initiated on endosome | ||||
| WikiPathways | Toll-like receptor signaling pathway | |||
| Toll-Like Receptors Cascades | ||||
| MyD88 dependent cascade initiated on endosome | ||||
| Trafficking and processing of endosomal TLR | ||||
| Regulation of toll-like receptor signaling pathway | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00189332) Use of 852A in Metastatic Cutaneous Melanoma.. U.S. National Institutes of Health. | |||
| REF 2 | ClinicalTrials.gov (NCT00810758) Multiple Oral Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-04878691. U.S. National Institutes of Health. | |||
| REF 3 | The innate immune response, clinical outcomes, and ex vivo HCV antiviral efficacy of a TLR7 agonist (PF-4878691). Clin Pharmacol Ther. 2011 Jun;89(6):821-9. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.